Aquestive Therapeutics, Inc. Investment Income, Interest
Aquestive Therapeutics, Inc. (AQST) reported Investment Income, Interest of $132.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-09.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2021-03-09
- Aquestive Therapeutics, Inc. investment income, interest for the quarter ending 2020-12-31 was $4.00K, a 94.37% decline year-over-year.
- Aquestive Therapeutics, Inc. investment income, interest for the quarter ending 2020-09-30 was $8.00K, a 94.20% decline year-over-year.
- Aquestive Therapeutics, Inc. investment income, interest for the quarter ending 2020-06-30 was $18.00K, a 88.24% decline year-over-year.
- Aquestive Therapeutics, Inc. investment income, interest for the quarter ending 2020-03-31 was $102.00K.
- Aquestive Therapeutics, Inc. investment income, interest for fiscal 2020 was $132.00K, a 79.25% decline from fiscal 2019.
- Aquestive Therapeutics, Inc. investment income, interest for fiscal 2019 was $636.00K.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2020-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $12.00K derived: sum of 2 quarters · filed 2021-03-09 | $30.00K derived: sum of 3 quarters · filed 2021-03-09 | $132.00K 10-K · filed 2021-03-09 |
| 2020-09-30 | $8.00K 10-Q · filed 2020-11-04 | $26.00K derived: sum of 2 quarters · filed 2020-11-04 | $128.00K 10-Q · filed 2020-11-04 | $199.00K derived: sum of 4 quarters · filed 2021-03-09 |
| 2020-06-30 | $18.00K 10-Q · filed 2020-08-04 | $120.00K 10-Q · filed 2020-08-04 | $191.00K derived: sum of 3 quarters · filed 2021-03-09 | $329.00K derived: sum of 4 quarters · filed 2021-03-09 |
| 2020-03-31 | $102.00K derived: 10-K 12 month − 3 quarters · filed 2021-03-09 | $173.00K derived: sum of 2 quarters · filed 2021-03-09 | $311.00K derived: sum of 3 quarters · filed 2021-03-09 | $464.00K derived: sum of 4 quarters · filed 2021-03-09 |
| 2019-12-31 | $71.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $209.00K derived: sum of 2 quarters · filed 2021-03-09 | $362.00K derived: sum of 3 quarters · filed 2021-03-09 | $636.00K 10-K · filed 2021-03-09 |
| 2019-09-30 | $138.00K 10-Q · filed 2020-11-04 | $291.00K derived: sum of 2 quarters · filed 2020-11-04 | $565.00K 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $153.00K 10-Q · filed 2020-08-04 | $427.00K 10-Q · filed 2020-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |